oxazoles has been researched along with 2019 Novel Coronavirus Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Cheng, Q; Fang, Z; Jia, Q; Zhao, G | 1 |
| Aswad, F; Enjuanes, L; Fortney, K; Klumpp, K; Li, K; Li, P; McCray, PB; Meyerholz, DK; Murakami, M; Narumiya, S; Ortiz, ME; Pan, R; Perlman, S; Pezzulo, AA; Rebo, J; Schnicker, NJ; Sola, I; Szachowicz, PJ; Thurman, A; Wilhelmsen, K; Wong, LR; Zheng, J; Zuniga, S | 1 |
| Fan, J; Fang, H; Jia, YC; Ju, MJ; Wang, H; Wang, XD; Yang, DW | 1 |
2 review(s) available for oxazoles and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azetidines; COVID-19; COVID-19 Drug Treatment; Humans; Imatinib Mesylate; Immunologic Factors; Network Meta-Analysis; Oxazoles; Purines; Pyrazoles; SARS-CoV-2; Severity of Illness Index; Sulfonamides; Thiohydantoins; Treatment Outcome | 2021 |
Proxalutamide for the treatment of COVID-19 rebound following Paxlovid treatment: Report of four cases and review of the literature.
Topics: COVID-19; Humans; Oxazoles | 2023 |
1 other study(ies) available for oxazoles and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19.
Topics: Animals; COVID-19; Eicosanoids; Leukocytes, Mononuclear; Mice; Organic Chemicals; Oxazoles; Piperazines; Polyesters; Prostaglandins; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Sulfonamides | 2022 |